Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study.
heart failure
hemodynamics
population
pressure
pulmonary artery
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
8
8
2020
medline:
20
3
2021
entrez:
8
8
2020
Statut:
ppublish
Résumé
Ambulatory hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for patients with New York Heart Association Class III heart failure (HF) and a prior HF hospitalization (HFH) within 12 months. The objective of this study was to assess the efficacy and safety of PA pressure-guided therapy in routine clinical practice with special focus on subgroups defined by sex, race, and ejection fraction. This multi-center, prospective, open-label, observational, single-arm trial of 1200 patients across 104 centers within the United States with New York Heart Association class III HF and a prior HFH within 12 months evaluated patients undergoing PA pressure sensor implantation between September 1, 2014, and October 11, 2017. The primary efficacy outcome was the difference between rates of adjudicated HFH 1 year after compared with the 1 year before sensor implantation. Safety end points were freedom from device- or system-related complications at 2 years and freedom from pressure sensor failure at 2 years. Mean age for the population was 69 years, 37.7% were women, 17.2% were non-White, and 46.8% had preserved ejection fraction. During the year after sensor implantation, the mean rate of daily pressure transmission was 76±24% and PA pressures declined significantly. The rate of HFH was significantly lower at 1 year compared with the year before implantation (0.54 versus 1.25 events/patient-years, hazard ratio 0.43 [95% CI, 0.39-0.47], In routine clinical practice as in clinical trials, PA pressure-guided therapy for HF was associated with lower PA pressures, lower rates of HFH and all-cause hospitalization, and low rates of adverse events across a broad range of patients with symptomatic HF and prior HFH. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02279888.
Sections du résumé
BACKGROUND
Ambulatory hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for patients with New York Heart Association Class III heart failure (HF) and a prior HF hospitalization (HFH) within 12 months. The objective of this study was to assess the efficacy and safety of PA pressure-guided therapy in routine clinical practice with special focus on subgroups defined by sex, race, and ejection fraction.
METHODS
This multi-center, prospective, open-label, observational, single-arm trial of 1200 patients across 104 centers within the United States with New York Heart Association class III HF and a prior HFH within 12 months evaluated patients undergoing PA pressure sensor implantation between September 1, 2014, and October 11, 2017. The primary efficacy outcome was the difference between rates of adjudicated HFH 1 year after compared with the 1 year before sensor implantation. Safety end points were freedom from device- or system-related complications at 2 years and freedom from pressure sensor failure at 2 years.
RESULTS
Mean age for the population was 69 years, 37.7% were women, 17.2% were non-White, and 46.8% had preserved ejection fraction. During the year after sensor implantation, the mean rate of daily pressure transmission was 76±24% and PA pressures declined significantly. The rate of HFH was significantly lower at 1 year compared with the year before implantation (0.54 versus 1.25 events/patient-years, hazard ratio 0.43 [95% CI, 0.39-0.47],
CONCLUSIONS
In routine clinical practice as in clinical trials, PA pressure-guided therapy for HF was associated with lower PA pressures, lower rates of HFH and all-cause hospitalization, and low rates of adverse events across a broad range of patients with symptomatic HF and prior HFH. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02279888.
Identifiants
pubmed: 32757642
doi: 10.1161/CIRCHEARTFAILURE.119.006863
pmc: PMC7434214
doi:
Banques de données
ClinicalTrials.gov
['NCT02279888']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e006863Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
Lancet. 2019 Mar 9;393(10175):1034-1044
pubmed: 30860029
Dtsch Arztebl Int. 2009 Oct;106(41):664-8
pubmed: 19946431
Circ Heart Fail. 2014 Nov;7(6):935-44
pubmed: 25286913
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
Lancet. 2016 Jan 30;387(10017):453-61
pubmed: 26560249
JAMA Intern Med. 2016 Mar;176(3):310-8
pubmed: 26857383
Assist Inferm Ric. 2001 Apr-Jun;20(2):104-7
pubmed: 11942195
J Am Coll Cardiol. 2008 Mar 18;51(11):1073-9
pubmed: 18342224
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
J Am Coll Cardiol. 2017 May 16;69(19):2357-2365
pubmed: 28330751
Annu Rev Med. 2018 Jan 29;69:65-79
pubmed: 29414252
Lancet. 2011 Feb 19;377(9766):658-66
pubmed: 21315441
Circulation. 2011 May 3;123(17):1873-80
pubmed: 21444883
ESC Heart Fail. 2018 Dec;5(6):1008-1016
pubmed: 30211480
Circulation. 2016 Mar 1;133(9):872-80
pubmed: 26927005
J Card Fail. 2015 Mar;21(3):240-9
pubmed: 25541376
N Engl J Med. 2010 Dec 9;363(24):2301-9
pubmed: 21080835
Circulation. 2012 Jan 3;125(1):e2-e220
pubmed: 22179539
Circ Heart Fail. 2010 Sep;3(5):596-605
pubmed: 20634483
J Card Fail. 2011 Apr;17(4):282-91
pubmed: 21440865
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366
pubmed: 30025570
J Am Coll Cardiol. 2007 Jan 16;49(2):171-80
pubmed: 17222727